In NAFLD model of rodents, dioscin could activate the SIRT1/AMPK signaling pathways to regulate genes (such as SREBP-1c and CPT) to attenuate lipid accumulation, suggesting the therapeutic effect of dioscin on NAFLD [24]. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.